Mylan Labs Affirms Guidance
The company expects fiscal 2004 earnings of $1.67 to $1.77 a share.
Mylan Laboratories
(MYL)
affirmed its fiscal 2004 earnings guidance Monday and also said it has started selling a generic version of
AstraZeneca's
(AZN)
Scroll to Continue
TheStreet Recommends
heartburn treatment Prilosec.
In a press release, Mylan said it expects fiscal 2004 earnings of $1.67 to $1.77 a share. Additionally, the company's Mylan Pharmaceuticals unit has started selling 10 mg and 20 mg omeprazole delayed-release capsules, the generic version of Prilosec.
Shares of Mylan were gaining 93 cents, or 2.8%, to $34.48 in recent
New York Stock Exchange
trading.
On average, analysts polled by Thomson First Call expect Mylan to earn $1.62 a share in fiscal 2004, which is already underway.
